David S. Snyder Email & Phone Number

Chicago, Il, Us

Helped prepare Coya for life as a public company and then helped Coya market and close its IPO in January of 2023. Upgraded financial reporting systems and internal controls to be SarbOx compliant. Helped negotiate and close two in-licensing transactions to secure rights to biologic assets comprising Coya's lead therapeutic. Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs.

Board member and Chair of Audit Committee. Invenra is focused on developing the next generation of best-in-class biologics, with an emphasis on multi-specific antibodies and their derivatives. Invenra has a growing pipeline of immuno-oncology bi-specific antibodies that are currently in pre-clinical studies. Announced partnerships with Exelixsis and WARF.

Georgetown, Tx, Us

DisperSol is a late stage bio-pharmaceutical company with four active clinical programs. DisperSol's drug for acquired resistance prostate cancer is currently enrolling in a Phase 2 dose expansion study and the company's iron chelator is preparing to launch a Phase 3 study. The Company has two additional programs completing Phase 1 studies and NCE in pre-clinical development. I was brought in to help the company manage a cross-over financing followed by an IPO.

Chicago, Illinois, Us

Exicure, Inc. is a clinical-stage biotechnology company developing drugs for immuno-oncology, neurological disorders and inflammatory diseases. Exicure's 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Exicure currently has a Phase 2 asset for immuno-oncology and various pre-clinical programs in neurology.Helped lead company through a $62.5 million confidentially marketed public offering (CMPO) and up-listing onto Nasdaq. Helped lead $27.5 million CMPO. Guided company through a reverse merger into a public shell and a concurrent $31.5 MM PIPE. Subsequently raised an additional $22.0 million in a PIPE. Managed registration of shares followed by public trading on OTC. Placed $25 million senior secured credit facility. Negotiated collaborative development agreement with Allergan for two programs with a $25 million upfront payment, $725 million in potential milestones and tiered royalties of mid-single digit to mid-teens percentages on worldwide net product sales.Broad responsibilities include: Capital raising, SEC compliance, corporate governance, board and board committee meetings, SarbOx, IR, financial accounting, cash management, HR, and general management.

Madison, Wi, Us

After successful sale of NimbleGen to Roche (see below), invited by same investor group to join this new life science start-up.CDI is commercializing stem cell technology developed by James Thomson at the University of Wisconsin. That technology (known as iPS) allows us to produce a fully pluripotent stem cell from adult skin and blood eliminating the ethical objections inherent in embryonic stem cell research. For the first time, researchers and industry can be offered fully functioning, normal, human cells of any somatic cell type from any genotype. CDI has raised over $164 million in capital and has over 125 employees making it one of the largest stem-cell focused companies in the world.Successfully completed IPO in July of 2013 (NASDAQ: ICEL). Books run by JP Morgan. Cowen and Leerink Co-managers.

Us

Brought in to lead IPO. Over 18 months, helped lead "Dual Track" process that led to an S1 filing in March of 2007 followed by the sale of NimbleGen to Roche for $272 Mil ... 22x revenue...in August of 2007. In addition to managing all financial operations, I had responsibility for production, customer service, technical service and quality control. Appointed Site Vice President by Roche subsequent to the closing.

Early-stage company supplying enterprise-class software to the healthcare industry. Financing from Portage/Draper Fisher Jurvetson and Hopewell Ventures.

Responsible for all financial functions, production, order fulfillment, investor relations, legal and process improvement at this NASDAQ-traded company. Cobalt provides Internet applications to franchised automobile dealers which enable online marketing, sales, and CRM. Reduced headcount by 50. Cured imminent debt default. Closed joint venture with GE Capital. Revamped budgeting process to achieve accurate earnings forecasts. Provided greater financial disclosure to Board. Initiated comprehensive system of performance metrics. Increased conservatism of revenue recognition policies. Introduced new internal financial controls and process disciplines in bidding and pricing. Guided $38 million going private transaction. Facilitated $15 million equity investment by Warburg Pincus and other institutions. Structured $10 million secured credit facility.

Joined this start-up venture three months after formation and helped lead its growth from start-up to nearly $3 billion assets. Initial equity provided by Goldman Sachs Whitehall Funds, Security Capital Group, Inc. and The Prudential Insurance Company. Strategic Hotel Capital, LLC acquires and asset manages luxury and upscale hotels. Within two years, the company invested $2.7 billion in 31 hotels with 12,600 rooms. Raised over $1.7 billion of debt and equity. Led team which executed a $600 million private placement of common stock and convertible debentures. Raised $1.1 billion of debt in the CMBS and bank markets to finance a $329 million repurchase of shares and recapitalize the company. Raised over $275 million in non-recourse financing including local currency transactions in London, Paris and Prague. Hedged currency exposure. Developed all accounting systems, policy and procedures. Created all financial forecasting, capital planning and budgeting tools. Developed all personnel policies.

Rejoined Sam Zell’s organization to help launch a new real estate investment firm. Developed strategic plan for the business and initial operating policies and procedures. Invested over $150 million in 12 parking facilities.Managed business operations. Responsible for acquisition analysis and investment committee proposals and recommendations.

Joined this Crane Co. subsidiary shortly after Crane’s acquisition of Mark Controls (see below). Led department of 24 responsible for all financial functions at this $150 million in sales manufacturer of electronic aerospace and telecommunications components. Direct report to unit president with dotted-line responsibility to Crane's chief financial officer. Helped lead organization through dramatic turnaround. Operating profit grew sharply from near break-even to in excess of $30 million. Rapidly restructured and right-sized the operation. Overhauled financial operations. Shortened closing cycle from two weeks to three days. Reduced delinquent receivables from $3.3 million to $400 thousand. Managed $11.3 million sale of redundant manufacturing and office building. Streamlined inventory by eliminating 2,500 part numbers. Initiated extensive product line reporting. Revitalized pricing and cost estimating procedures.

Jump-started growth and value creation at this NASDAQ traded manufacturer of electronic and electromechanical instruments, controls and industrial valves. Sales of $135 million up over 50% in one year. Raised $53 million and completed two acquisitions to grow the business. Negotiated $30 million term loan and $23 million revolving credit facility to finance acquisition activity. Generated 119% stock premium through well-timed sale of business. Joined CEO and outside advisors in planning and executing strategy for maximizing the value of the company in the face of a hostile $13 per share bid. Led public company finance organization. Managed professional staff of five at corporate office with dotted-line responsibility for eight unit controllers. Responsible for all internal and external financial reporting and regulatory compliance. Responsible for day-to-day contact with shareholders, financial analysts, and media. Managed all corporate administrative activities including taxes, risk and insurance, employee pension and welfare plans, pension fund management, transfer agent and NASDAQ relationships.

The Equity Group is a holding company for the investment interests of Chicago real estate andfinancial entrepreneur Sam Zell. Started in investment analysis at EGI and then joined Eagle Industries. Held positions of increasing responsibility. Eagle is a diversified manufacturing company. Started acquisition group at beginning of major acquisition initiative; sales grew from about $500 million to over $1.3 billion through acquisition and internal growth.Managed staff of five responsible for preparation and analysis of corporate budget and financial forecasts. Managed debt compliance. Administered annual strategic planning process. Conducted IPO planning. Developed strategy and action plan to restructure Eagle's approximately $325 million of bank debt and $375 million of public subordinated debt.Responsible for valuation and strategic analysis of numerous acquisitions with value in excess of $1 billion.

Mba

Ba, Economics